| |
| Device | VENTANA ALK (D5F3) CDX ASSAY |
| Generic Name | Immunohistochemistry assay, antibody, anaplastic lymphoma kinase |
| Applicant | Ventana Medical Systems, Inc. 1910 E. Innovation Park Dr. Tucson, AZ 85755 |
| PMA Number | P140025 |
| Date Received | 11/14/2014 |
| Decision Date | 06/12/2015 |
| Product Code |
PKW |
| Docket Number | 15M-2219 |
| Notice Date | 07/10/2015 |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT00585195
|
| Expedited Review Granted? | No |
| Combination Product | Yes |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement APPROVAL FOR THE VENTANA ALK (D5F3) CDX ASSAY. THIS DEVICE IS INDICATED FOR THE FOLLOWING:VENTANA ALK (D5F3) CDX ASSAY IS INTENDED FOR THE QUALITATIVE DETECTION OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SMALL CELL LUNG CARCINOMA (NSCLC) TISSUE STAINED WITH A BENCHMARK XT AUTOMATED STAINING INSTRUMENT. IT IS INDICATED AS AN AID IN IDENTIFYING PATIENTS ELIGIBLE FOR TREATMENT WITH XALKORI® (CRIZOTINIB). |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Supplements: |
S004 S007 S002 S001 S003 S005 S006 S009 S010 S012 S020 S015 S025 S023 S013 S011 S014 S018 S021 S016 S017 S024 S022
|